LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Microbot Medical Inc

Chiusa

2.17 4.33

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.05

Massimo

2.36

Metriche Chiave

By Trading Economics

Entrata

-77K

-3.6M

Dipendenti

20

EBITDA

-79K

-3.6M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+307.61% upside

Dividendi

By Dow Jones

Utili prossimi

23 mar 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-17M

124M

Apertura precedente

-2.16

Chiusura precedente

2.17

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

Microbot Medical Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 feb 2026, 23:57 UTC

Azioni calde

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 feb 2026, 23:35 UTC

Utili
I principali Market Mover

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 feb 2026, 23:28 UTC

Utili

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 feb 2026, 21:47 UTC

Utili

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 feb 2026, 00:00 UTC

Discorsi di Mercato

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 feb 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 feb 2026, 23:38 UTC

Discorsi di Mercato

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 feb 2026, 23:33 UTC

Utili

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 feb 2026, 23:09 UTC

Discorsi di Mercato

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 feb 2026, 22:55 UTC

Utili
Azioni calde

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 feb 2026, 22:46 UTC

Discorsi di Mercato

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 feb 2026, 22:23 UTC

Utili

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 feb 2026, 22:15 UTC

Utili

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 feb 2026, 22:15 UTC

Utili

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 feb 2026, 22:15 UTC

Utili

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 feb 2026, 22:15 UTC

Utili

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 feb 2026, 22:00 UTC

Utili

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb 2026, 22:00 UTC

Utili

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 feb 2026, 22:00 UTC

Utili

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 feb 2026, 22:00 UTC

Utili

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 feb 2026, 22:00 UTC

Utili

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb 2026, 22:00 UTC

Utili

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 feb 2026, 21:57 UTC

Utili

XP 4Q Rev BRL4.95B >XP

12 feb 2026, 21:52 UTC

Utili

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb 2026, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

12 feb 2026, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

12 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 feb 2026, 21:47 UTC

Utili

Morningstar 4Q Rev $641M >MORN

12 feb 2026, 21:39 UTC

Utili

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb 2026, 21:38 UTC

Utili

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Microbot Medical Inc Previsione

Obiettivo di Prezzo

By TipRanks

307.61% in crescita

Previsioni per 12 mesi

Media 7.5 USD  307.61%

Alto 12 USD

Basso 5 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Microbot Medical Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.52 / 2.57Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Very Strong Bullish Evidence

A lungo termine

Weak Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
help-icon Live chat